Adding immune modulators to targeted therapy, according to a trial, did not increase survival in thyroid cancer patients who are difficult to treat.

Published Date: 06 Sep 2023

A targeted tyrosine kinase inhibitor (TKI) should be used in combination with an immunomodulatory agent, according to the findings of a multicenter phase II clinical trial directed by the University of Chicago Medicine Comprehensive Cancer Center.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot